Last updated: June 23, 2026
Bristol-Myers Squibb v. Aurobindo Pharma USA (1:17-cv-00374): Litigation Summary, Patent Scope, and Generic Entry Risk
Bristol-Myers Squibb (BMS) sued Aurobindo Pharma USA, Inc. in the US District Court for the District of Delaware under the Hatch-Waxman framework, seeking to block Aurobindo’s proposed generic entry based on Orange Book-listed patents for a BMS drug. The docket number provided identifies the case but not the asserted drug, asserted patents, or procedural posture needed to produce an accurate, patent-level litigation analysis (assertion-by-assertion, expiration and exclusivity alignment, and launch risk mapping).
What patents are asserted in BMS v. Aurobindo 1:17-cv-00374
No asserted patent numbers, patent claims, or Orange Book listing details are provided with the case identifier. Without the complaint, exhibit list, or asserted-patent record, a complete and accurate patent scope analysis cannot be produced.
Which Orange Book patents are in dispute
Patent numbers and publication/application links are not included. This prevents identification of:
- the specific composition, formulation, method-of-use, and/or manufacturing patents asserted
- the statutory bases under 35 USC § 271(e)(2) (infringement for “substantial likelihood” post-approval)
- the specific Orange Book listings (drug product, strength, dosage form) tied to the filing
What claims are targeted (composition vs. method-of-use vs. formulation)
The case identifier alone does not specify whether BMS asserted:
- active ingredient/chemical structure claims (composition)
- specific salt/polymorph/hydrate forms (solid-state/formulation)
- dosing regimens or patient subpopulations (method-of-use)
- manufacturing process claims
When does exclusivity expire for the drug in dispute
The expiration/exclusivity timeline depends on the underlying FDA-approved reference product and the Orange Book patent/exclusivity bundle. The docket number provided does not identify:
- the reference listed drug (RLD)
- the New Chemical Entity (NCE) or biologic exclusivity basis (if any)
- relevant patent-by-patent expiration dates and any pediatric exclusivity extensions
What Paragraph IV challenges are at issue
A “Paragraph IV” characterization requires the asserted-patent set and the ANDA filer’s certification (e.g., 35 USC § 355(j)(2)(A)(vii)(IV)) against specific Orange Book patents. That content is not present.
Do the arguments map to non-infringement, invalidity, or both
A litigation analysis requires the claim-by-claim theories raised in the pleadings (non-infringement, invalidity under §§ 102/103/112 or other statutory grounds). None of those details are included with the docket identifier.
How strong is the patent estate for BMS against Aurobindo
Strength scoring requires, at minimum:
- the asserted patent set
- remaining life and claim breadth
- prosecution history indicators relevant to invalidity risk
- whether any asserted patents have been previously litigated or survived prior challenges
No such inputs are included, so an estate-strength conclusion cannot be produced from the provided information alone.
What is the Orange Book status of the BMS patents in this case
Orange Book status requires the drug’s RLD, dosage form, strengths, and listing-by-listing identifiers (US patent numbers) linked to BMS. The case identifier alone cannot be converted into an Orange Book table.
What is the litigation procedural posture in 1:17-cv-00374
A procedural posture summary requires court filings and dates such as:
- complaint filing date and service date
- answer and counterclaims
- motions to dismiss, claim construction, summary judgment
- Markman schedule (if applicable)
- trial date or dispositive order entries
- any settlement or consent judgment entry
No docket events or order dates are included with the prompt, so a truthful procedural timeline cannot be generated.
What generic entry risks exist for Aurobindo after the BMS suit
Launch risk depends on at least four elements:
- the ANDA approval status (tentative/approved)
- the specific patents blocked (and their remaining expiration)
- any injunction scope (temporary/ongoing) and carve-outs
- any settlement terms that accelerate or delay entry
None of these are provided.
How does Aurobindo’s proposed ANDA design avoid or trigger infringement
Aurobindo’s proposed product and labels are required to assess:
- salt form/polymorph and bioequivalence strategy
- formulation differences vs. asserted formulation patents
- dosing and patient population differences vs. method-of-use patents
- manufacturing process differences vs. process claims
No ANDA product details or infringement content is included.
What settlements or consent judgments govern entry
Settlement terms must be cited by docket event and agreement summary (entry date triggers, stipulated carve-outs, “at-risk” provisions, licensing scope). None are included.
How does this case compare with other BMS vs. generic challenges
A comparison requires knowing:
- which BMS product is involved
- which generic challengers and which asserted patent bundles
- how courts have handled validity/infringement in related matters
The drug identity is missing.
Which jurisdictional issues could affect enforceability (Delaware vs. Federal Circuit)
Jurisdiction and appellate pathway analysis requires the orders appealed and the posture at time of appeal. No filings are provided.
Key Takeaways
- The docket identifier “Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. | 1:17-cv-00374” is not sufficient to generate a litigation summary that is patent-accurate, Orange Book-linked, or launch-risk actionable.
- No asserted patents, procedural dates, injunction/settlement terms, or FDA/ANDA status are included in the input, preventing an evidence-based analysis.
FAQs
- What is the asserted-drug identity in BMS v. Aurobindo 1:17-cv-00374?
- Which specific Orange Book patents were challenged under Paragraph IV in 1:17-cv-00374?
- What is the timeline from complaint filing to any dispositive ruling or settlement entry for 1:17-cv-00374?
- Do any asserted BMS patents expire before or after the ANDA approval date for the generic product in this case?
- Was there a consent judgment or licensing settlement that permits earlier or at-risk generic entry?
References
(No citable source content is provided in the prompt beyond the docket identifier.)
